164 related articles for article (PubMed ID: 22184375)
1. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer.
Nelson PS
J Clin Oncol; 2012 Feb; 30(6):644-6. PubMed ID: 22184375
[No Abstract] [Full Text] [Related]
2. Role of androgens in abiraterone resistance.
Colloca G
J Clin Oncol; 2012 Oct; 30(28):3561-2: author reply 3562. PubMed ID: 22915660
[No Abstract] [Full Text] [Related]
3. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.
Efstathiou E; Titus M; Tsavachidou D; Tzelepi V; Wen S; Hoang A; Molina A; Chieffo N; Smith LA; Karlou M; Troncoso P; Logothetis CJ
J Clin Oncol; 2012 Feb; 30(6):637-43. PubMed ID: 22184395
[TBL] [Abstract][Full Text] [Related]
4. Expanding treatment options for metastatic prostate cancer.
Antonarakis ES; Eisenberger MA
N Engl J Med; 2011 May; 364(21):2055-8. PubMed ID: 21612475
[No Abstract] [Full Text] [Related]
5. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer.
Yamaoka M; Hara T; Kusaka M
Clin Cancer Res; 2010 Sep; 16(17):4319-24. PubMed ID: 20647476
[TBL] [Abstract][Full Text] [Related]
6. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
7. Targeting the androgen receptor in prostate cancer--a resilient foe.
Nelson PS
N Engl J Med; 2014 Sep; 371(11):1067-9. PubMed ID: 25184629
[No Abstract] [Full Text] [Related]
8. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
[No Abstract] [Full Text] [Related]
9. Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore.
Goldkorn A; Aparicio AM; Quinn DI
Ann Oncol; 2013 Jul; 24(7):1717-1720. PubMed ID: 23798673
[No Abstract] [Full Text] [Related]
10. New therapeutic agents for castration-refractory prostate cancer.
Patten DY; Sartor O
Clin Genitourin Cancer; 2009 Aug; 7(2):E4-6. PubMed ID: 19692323
[No Abstract] [Full Text] [Related]
11. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone and castration-resistant prostate cancer.
Burki TK
Lancet Oncol; 2013 Feb; 14(2):e48. PubMed ID: 23487849
[No Abstract] [Full Text] [Related]
13. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
Attard G; Belldegrun AS; de Bono JS
BJU Int; 2005 Dec; 96(9):1241-6. PubMed ID: 16287438
[No Abstract] [Full Text] [Related]
14. [Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
Takeda M; Hosaka M
Nihon Rinsho; 2000 Jul; 58 Suppl():312-6. PubMed ID: 11022738
[No Abstract] [Full Text] [Related]
15. [New drugs in metastatic castration-resistant prostate cancer].
Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone and increased survival in metastatic prostate cancer.
Sonpavde G
N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
[No Abstract] [Full Text] [Related]
17. Novel concepts in androgen receptor blockade.
Hsieh AC; Ryan CJ
Cancer J; 2008; 14(1):11-4. PubMed ID: 18303477
[TBL] [Abstract][Full Text] [Related]
18. Abiraterone and increased survival in metastatic prostate cancer.
Berruti A; Pia A; Terzolo M
N Engl J Med; 2011 Aug; 365(8):766; author reply 767-8. PubMed ID: 21864182
[No Abstract] [Full Text] [Related]
19. Abiraterone acetate for the treatment of prostate cancer.
Ryan CJ; Cheng ML
Expert Opin Pharmacother; 2013 Jan; 14(1):91-6. PubMed ID: 23199349
[TBL] [Abstract][Full Text] [Related]
20. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer.
Zhang X
Cancer Commun (Lond); 2019 Nov; 39(1):76. PubMed ID: 31753020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]